ERRATUM

Erratum to: Efficient design, synthesis and structure–activity relationship studies of 1-(3'-substituted propyl)-4-arylpiperidines as non-peptide antagonists of nociceptin/orphanin FQ receptor: biological activities, metabolic stabilities and hERG channel bindings

Shigeo Hayashi · Katsuyo Ohashi ·
Eriko Nakata · Chie Emoto

Published online: 2 August 2013
© Springer Science+Business Media New York 2013

Erratum to: Med Chem Res
DOI 10.1007/s00044-013-0595-3

The original version of this article unfortunately contained an error. An incorrect phrase was included. The correct sentence should read as given below.

Section “Introduction”, first paragraph, lines 43–52, the second last sentence of the paragraph should read: “Actually, we have been reported the discovery of highly selective and

potent new-class non-peptide NOP receptor full agonists in the distinct two series of drug-design, synthesis and structure–activity relationship (SAR) studies by Hayashi *et al.* (2009a, b, 2010), respectively, thus, HPCOM as a systemically potent new-class analgesic for the treatment of neuropathic pain, and MCOPPB as an orally potent new-class anxiolytic, with robust metabolic stabilities and little potential risks of human *ether-a-go-go* related gene (hERG) ion channel binding issues, respectively.”

The online version of the original article can be found under doi:[10.1007/s00044-013-0595-3](https://doi.org/10.1007/s00044-013-0595-3).

S. Hayashi (✉) · K. Ohashi · E. Nakata · C. Emoto
Nagoya Laboratories, Pfizer Global Research & Development,
Pfizer Japan Inc., 5-2 Taketoyo, Aichi 470-2393, Japan
e-mail: Shigeo_Hayashi@nifty.com